

Seroconversion:	no	yes	<i>p</i>
n	45	29	
Age (mean (SD))	60.07 (14.40)	64.25 (10.99)	0.187
Gender: female (%)	39 (86.7)	18 (62.1)	0.023
Diagnosis n (%)			0.113
IgG4-related Disease	1 (2.2)	1 (3.4)	
Connective Tissue Disease	17 (37.8)	5 (17.2)	
Rheumatoid Arthritis	20 (44.4)	13 (44.8)	
Vasculitis	7 (15.6)	10 (34.5)	
Peripheral B cells, absolute (median [IQR])	0.00 [0.00, 0.00]	42.00 [23.00, 109.00]	<0.001
Detectable B cells (%)	10 (22.2)	28 (96.6)	<0.001
IgG (median [IQR]) mg/dL	781 [643, 987]	962 [691, 1183]	0.216
IgM (median [IQR]) mg/dL	39 [25, 65]	48 [30, 73]	0.315
Months between RTX and Vaccination (mean (SD))	5.0 (3.8)	9.8 (7.5)	0.001
Days between Vaccine and Laboratory assessment (mean (SD))	21.2 (15.4)	21.5 (15.6)	0.937
Concomitant Medication n (%)			
Any csDMARD	26 (57.8)	16 (55.2)	1.000
Methotrexate	14 (31.1)	10 (34.5)	0.803
Mycophenolate Mofetil	6 (13.3)	2 (6.9)	0.469
Hydroxychloroquine	4 (8.9)	3 (10.3)	1.000
Azathioprine	4 (8.9)	1 (3.4)	0.642
Leflunomide	2 (4.4)	2 (6.9)	0.642
Sulfasalazine	0 (0.0)	1 (3.4)	0.392
Immunoglobulin therapy	3 (6.7)	0 (0.0)	0.275
Prednisone	14 (31.1)	8 (27.6)	0.800
Vaccine n (%)			0.115
mRNA-1273	5 (11.1)	8 (27.6)	
BNT162b2	40 (88.9)	21 (72.4)	
SARS Cov2-S Antibodies U/ml (median [IQR])	0.0 [0.0, 0.0]	64.9 [16.2, 2161.0]	<0.001
T-cell response n (%)	14 (51.9)	12 (66.7)	0.371

Mean T cell response per SFCs/10 ⁶ PBMCs	138.94 (149.51)	185.01 (180.84)	0.357
---	-----------------	-----------------	-------

Supplemental Table 1: Patient characteristics stratified by seroconversion